Is Upatinib a biological agent? Professional answers

Upadatinib is an oral medication classified as a Janus kinase (JAK) inhibitor and not a biologic. This classification is based on its drug composition and mechanism of action. Upadatinib is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, active nonradiographic axial spondyloarthritis, and atopic dermatitis (eczema). Upadatinib provides patients with a new treatment option when other traditional treatments fail.

Different from biological agents, upadatinib is a small molecule compound that can selectively inhibit the activities of JAK1 and JAK2. The JAK-STAT signaling pathway plays a key role in inflammation and immune response. Upadatinib blocks key signaling in this pathway, thereby regulating the overactive immune system, reducing the production of inflammatory factors, and alleviating disease symptoms. This mechanism of action makes upadatinib excellent in treating the above-mentioned autoimmune diseases, especially when other treatments have not been effective.

The use of upadatinib needs to strictly follow the doctor's advice, because it may cause some side effects, including abnormal liver function and increased risk of infection. In addition, special caution is required when using upadacitinib for specific groups of people, such as pregnant and lactating women, and patients with severe liver and renal impairment.

In short, upadatinib is a highly effectiveJAK inhibitor. Although it is not a biological agent, it has shown unique advantages in the treatment of various autoimmune diseases. Patients must fully understand the potential risks when using it and use it rationally under the guidance of a doctor.

References:

https://www.drugs.com/rinvoq.html